8-K - Pyxis Oncology, Inc. (0001782223) (Filer)

Wed, Aug 14, 8:25 PM (32 days ago)

On August 14, 2024, Pyxis Oncology, Inc. reported its financial results for Q2 2024, alongside a corporate update, via a press release (Exhibit 99.1). The company continues to operate as an emerging growth entity under SEC regulations. The report did not disclose specific financial figures, but it indicated ongoing developments relevant to investors. The information provided in the 8-K filing is not considered "filed" under the Securities Exchange Act, meaning it does not carry the same legal implications. The report was signed by CFO and COO Pamela Connealy, affirming compliance with SEC requirements. The stock trades under the symbol PYXS on the Nasdaq Global Select Market. This update may influence investor sentiment and stock performance, pending further details on financial metrics and strategic initiatives outlined in the press release.